Wegovy 4 Week Results: What Most People Notice First

Why the four-week mark isn't the fairest test of Wegovy

The decision most people face at week four is whether the medicine is doing anything at all. It's a fair question. But the dosing structure shapes the answer in ways that aren't obvious from the outside.

Wegovy's titration ladder starts at 0.25mg weekly. That first dose exists to help your body settle into the medicine (reduce early nausea, let your gut adapt) rather than to deliver maximum appetite suppression. Most people stay at 0.25mg for four weeks before their prescriber moves them to 0.5mg. So if your results at week four feel underwhelming, that's partly by design. You're at the base of a step-ladder that runs all the way to 2.4mg (or, with the newer pen, up to 7.2mg, following MHRA approval in April 2026).

What the full timeline of how long Wegovy takes to work shows is that meaningful average weight loss in trials accumulated over months, not weeks. The STEP 1 trial, which tracked nearly 2,000 adults over 68 weeks, reported around 15% average body-weight reduction at the end of the study, that trajectory begins slowly. STEP 1, published in the New England Journal of Medicine, remains the primary evidence base for semaglutide 2.4mg in weight management.

One practical thing that often matters more than the number on the scales at week four: whether your appetite has changed. Many people notice food feels less urgent, portions feel like enough, and the pull toward habitual snacking quietly weakens. That's the medicine working, even when the scales are slow to agree.

What the first four weeks typically feel like, and what to watch

Understanding what's normal in week four helps you decide whether to stay the course or flag something with your prescriber.

On the positive side: reduced appetite, a lower ceiling on how much feels comfortable to eat, and sometimes a shift in food preferences, highly processed or fatty foods can feel less appealing. Some people notice these changes in weeks one or two; others find they arrive closer to dose increases. You can read more about what the first week on Wegovy commonly involves, and how week two tends to differ once the initial adjustment settles.

On the side-effect side: nausea is the most commonly reported experience in the early weeks. Bloating, looser stools or constipation, mild indigestion, and a general sense of fullness after small amounts of food are all reported. The NHS semaglutide medicines page sets out which side effects are common versus which need prompt medical attention, it's worth bookmarking alongside your patient information leaflet, not least because it's updated when the evidence changes.

Keep your pen in the fridge door where you'll see it, a small habit that makes the weekly injection less easy to forget as dose increases come and your routine builds around it.

If you experience severe or persistent stomach pain that travels through to your back, seek medical help promptly rather than waiting for your next review. That symptom pattern needs a clinician's assessment the same day.

Comparing week four with what comes next

Week four is the end of chapter one, not the verdict. The real question isn't 'how much have I lost?' but 'is the medicine doing what it should at this stage, and am I ready to step up?'

By week eight, most people have moved to 0.5mg or are approaching it, and average losses reported in the trial begin to accumulate more meaningfully. Our page on Wegovy 8-week results covers what that stage typically looks like. Between now and then, weeks five, six and seven are the stretch where many people notice appetite suppression becoming more consistent, what week six typically brings gives a realistic reference point for that middle phase.

The cumulative shape of the STEP 1 trial data suggests the steepest rate of loss tends to occur after the maintenance dose is reached and stabilised. That matters when you're at week four: a small number now doesn't mean a small number at month six. For a fuller picture of the timeline, the Wegovy treatment overview covers the full dosing schedule and the evidence behind it.

If week four's results are prompting a question about cost versus value, the context around Wegovy pricing in the UK is worth reading alongside this, not because the price changes the biology, but because understanding what a legitimate private prescription includes helps you assess options clearly.

When to speak to your prescriber about four-week results

Most four-week check-ins are routine. But there are situations that warrant a conversation rather than a wait-and-see approach.

Contact your prescriber or healthcare team if: side effects are severe enough to affect eating, sleeping or daily function; you're experiencing persistent nausea that isn't settling; you have any doubt about whether the injection technique is correct; or the appetite changes you expected haven't arrived by week four and you're wondering about dose timing.

What a prescriber is not likely to recommend at week four is stopping, unless there's a clinical reason. Early results at the starting dose are almost never the basis for a final call on whether the medicine suits you. Patience in month one is frustrating but clinically sound.

If you haven't yet started and are trying to decide whether Wegovy is the right route, speaking to a prescriber is the practical next step. At nume, a free consultation connects you with a GPhC-registered independent prescriber who reviews your case the same day, a real clinician, not an automated queue. Our clinical team page explains who's doing that reviewing.